Search results
Results from the WOW.Com Content Network
The pharmaceutical industry in Pakistan was estimated to be worth Rs. 748 billion (US$2.6 billion) in 2023, representing about 1% of the country's GDP. [1] The industry is largely import-dependent, with more than 90% of raw material being imported and only 12% of active pharmaceutical ingredients locally produced. [1]
Metformin is the British Approved Name (BAN), the United States Adopted Name (USAN), and the International Nonproprietary Name (INN). It is sold under several brand names . Common brand names include Glucophage, Riomet, Fortamet, and Glumetza in the US. [ 176 ]
It is a highly selective dipeptidyl peptidase-4 inhibitor that is typically used as an add on treatment when the first line treatment of metformin is not achieving the expected glycemic goals; though it has been approved for use as a first line treatment when metformin cannot be used. [1]
Trade name 2018 sales (million USD) 2017 sales (million USD) 1 adalimumab: rheumatoid arthritis: Humira 19 936 18427 3 apixaban: anticoagulant: Eliquis 9872 7395 4 lenalidomide: multiple myeloma: Revlimid 9685 8187 5 nivolumab: oncology: Opdivo 7570 5763 6 pembrolizumab: oncology: Keytruda 7171 3809 7 etanercept: rheumatoid arthritis: Enbrel ...
Upload file; Search. Search. Appearance. ... Download as PDF; Printable version; ... also known as glyburide/metformin and sold under the brand name Glucovance, ...
Timing is everything for many things in life — including when to take medication like metformin, sold under the brand names Glucophage®, Fortamet®, Riomet®, and Glumetza®. 4 Tips for Knowing ...
Combination of sulfonylureas plus metformin – known by generic names of the two drugs; No generics are available for dipeptidyl peptidase-4 inhibitors (Onglyza), the glifozins, the incretins and various combinations. Sitagliptin patent expired in July 2022, leading to launch of generic sitagliptin [57] brands . This lowered the cost of ...
In the United States, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [5] [6]In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people ...